

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 61 (2005) 2279-2286

Silver (I)-promoted asymmetric halohydrin reaction of chiral *N*-enoyl-2-oxazolidinones: scope and limitations

Saumen Hajra,* Ananta Karmakar and Manishabrata Bhowmick

Department of Chemistry, Indian Institute of Technology, Salua road, Kharagpur 721 302, India

Received 7 October 2004; revised 21 December 2004; accepted 14 January 2005

Available online 1 February 2005

Abstract—The halohydrin reaction of chiral *N*-enoyl-2-oxazolidinones **1** by halogen (Br_2/I_2) and water were efficiently carried out in aqueous organic solvent promoted by silver(I) with high anti- and regioselectivity and moderate to good diastereoselectivities. The alkenoyl, cinnamoyl and electron-deficient cinnamoyl substrates smoothly underwent bromohydrin reaction in aqueous acetone but no iodohydrin reaction, where as electron-rich cinnamoyl substrates preferred to undergo iodohydrin reaction in aqueous acetone with moderate diastereoselectivity and enhanced diastereoselectivity was observed in aqueous THF. © 2005 Elsevier Ltd. All rights reserved.

1. Introduction

Carboxyhalohydrins especially α-halo-β-hydroxycarboxylic acid derivatives are versatile and useful synthetic intermediates because of their facile transformation to a variety of important compounds. These moieties are present in precursors to many biologically active compounds.¹ Carboxyhalohydrins are also good precursors for stereoselective radical reactions.² A potentially straightforward method for the synthesis of carboxyhalohydrins is the stereoselective halohydrin reaction of α,β -unsaturated carboxylic acid derivatives.³ Only few reports on the asymmetric halohydrin reaction are known in literature.^{4–6} Henry et al. first reported palladium(II)-catalyzed enantioselective hydroxychlorination of terminal alkenes with a metal chloride-mechanistically it is a hydroxychlorination to alkenes and there is no involvement of halonium (X^+) intermediate.⁴ Sudalai et al. described NaIO₄ mediated oxidative enantioselective halohydrination of alkenes (encapsulated in β -cyclodextrin) using alkali metal halides with moderate enantioselectivity.⁵ Barluenga et al. reported a highly diastereoselective iodohydrination of terpene derivatives using Py₂IBF₄.⁶

There are only a few methods, other than halohydrin reaction, for the stereoselective synthesis of the α -halo- β -hydroxycarboxylic acid derivatives.^{7–9} Reagent controlled aldol reaction of chiral α -halogenated imide enolates with

suitable aldehydes provide selectively both *anti*- and *syn-α*-halo- β -hydroxycarboxylic acid derivatives.⁷ Genet et al. reported the catalytic asymmetric hydrogenation of α -chloro- β -ketocarboxylic acid esters for the enantioselective synthesis of α -chloro- β -hydroxycarboxylic acid esters.⁸ Under controlled reaction conditions, epoxide ring opening of β -alkyl- α , β -epoxycarboxylic acids/derivatives provide stereoselectively α -halo- β -hydroxy-, as well as α -hydroxy- β -halocarboxylic acids/derivatives.⁹ However, epoxide ring opening of the β -aryl- α , β -epoxycarboxylic acid derivatives with halides give either poor regioselectivity or selectively α -hydroxy- β -halocarboxylic acid derivatives.⁹

In this paper we report in full the silver(I)-promoted asymmetric halohydrin reaction of chiral *N*-enoyl-2-oxazo-lidinones $\mathbf{1}$,¹⁰ in which high regio- and diastereoselectivities up to 82:18 of *anti*- α -halo- β -hydroxy carbonyls **3** and **4** with good yields are demonstrated.

2. Results and discussion

Initially (4*S*)-*N*-cinnamoyl-4-(1-methylethyl)-2-oxazolidinones were selected as substrates for the development of the diastereoselective halohydrin reaction. It was assumed that the β -aryl group of the three-member halonium intermediate **2** would enhance the electrophilicity towards the water nucleophile to achieve high regioselectivity (Scheme 1; R=Ar and R'=*i*-Pr) and also these carboxyhalohydrins are very important precursors to many biologically active compounds.¹ Moreover our research group is involved in the chelation controlled stereoselective radical

Keywords: Asymmetric; Halohydrin; Silver (I); Halogen (Br_2/I_2); *N*-enoyl-2-oxazolidinones; α -Halo- β -hydroxy carboxylic acid derivatives.

^{*} Corresponding author. Tel.: +91 3222 283340; fax: +91 3222 255303; e-mail: shajra@chem.iitkgp.ernet.in

^{0040–4020/\$ -} see front matter @ 2005 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2005.01.053



Scheme 1.

reaction of chiral β -aryl- α -halo- β -oxycarboxylic acid esters for the enantioselective synthesis of lignans.¹¹ However, there is no suitable method, other than the aldol reaction,⁷ for the synthesis of the chiral β -aryl- α -halo- β -oxycarboxylic acid derivatives.

There are only a few reports for the halohydrin reactions of α , β -unsaturated carbonyls.^{2d,3,12} By screening these methods, we found that halogen (Br₂/I₂) and silver nitrate (AgNO₃) is an effective combination for the halohydrin reaction of *N*-cinnamoyl-2-oxazolidinoes **1** over aromatic electrophilic substitutions. Halohydrin reaction of **1a** (R = Ph and R'=*i*-Pr) with Br₂ and AgNO₃ in aqueous acetone gave the desired carboxybromohydrine, along with a minor amount of a non-separable mixture of diastereoisomers (dr 60:40) of a dibromo compounds -*anti*-(4*S*)-3-(2',3'-dibromo-3'-phenyl-propionyl)-4-(1-methylethyl)-2-oxazolidinone (**5a**). The formation of **5a** varied with the amount of water in the reaction media. A systematic study showed that when the acetone/water ratio was maintained between 4:1

and 6:1, it gave >95:05 of carboxybromohydrins; lower as well as higher amount of water enhanced the formation of **5a**. The compound **5a** was characterized by the ¹H and ¹³C NMR spectra analysis and compared with the authentic dibromo compound, prepared on reaction of **1a** with Br₂ in CCl₄. It was also found that there was no reaction in 50% aqueous acetone and no appreciable change in the product distribution when the concentrations of the reaction medium were varied between 0.1 M and 0.5 M in a 4:1 (v/v) acetone/ water ratio. All halohydrin reactions were performed in aqueous organic solvent (solvent: H₂O, 4:1 v/v) at 0.2 M concentration.

To establish suitable reaction conditions, initially AgNO₃promoted halohydrin reactions of three electronically different cinnamoyl substrates 1a-1c, containing (4S)-4-(1-methylethyl)-2-oxazolidinone as chiral auxiliary were studied (Table 1). When a solution of 1a in aqueous acetone (acetone/water 4:1) was treated with AgNO₃ (1.2 equiv) and Br₂ (1.2 equiv) at rt (25 °C), it gave the desired carboxybromohydrin with poor diastereoselectivity (dr 52:48; entry 1) and the diastereomeric ratio was increased to 65:35 (entry 2) when the reaction was performed at 0-5 °C. The bromohydrin reaction of **1a** in aqueous acetonitrile was comparable (entry 3) with aqueous acetone. However, there was no bromohydrin reaction in aqueous DMF, DMSO and THF (entry 4). Iodohydrin reaction of 1a under the same reaction conditions gave <5% of the desired compounds (entry 5), also there was no improvement even with the use of excess reagents and under different reaction conditions. While the bromohydrin reaction of 1b was performed under the same reaction conditions, it gave mixture of products (entry 6). However, 1b smoothly underwent iodohydrin reaction with 70:30 diastereoselectivity (entry 8) in aqueous acetone. There is no appreciable change in diastereomeric ratio and yield when the reaction was performed at rt (25 °C) (entry 7). Unlike 1a, 1b underwent iodohydrin reaction in aqueous THF with improved diastereoselectivity of 80:20 (entry 9). Bromohydrin reaction was also studied for the

 Table 1. AgNO₃-promoted halohydrin reactions of 1 under different reaction conditions

	Substrate	R	R ₁	Solvent	Х	Ratio ^a (3 : 4)	Yield ^b (%)
1 ^c	1a	Ph	<i>i</i> -Pr	Acetone	Br	52:48 (55:45)	88
2	1a	Ph	<i>i</i> -Pr	Acetone	Br	65:35 (66:34)	92
3	1a	Ph	<i>i</i> -Pr	CH ₃ CN	Br	64: 36 (62:38)	82
4	1a	Ph	<i>i</i> -Pr	DMF or DMSO or THF	Br		NR
5	1 a	Ph	<i>i</i> -Pr	Acetone or THF or CH ₃ CN	Ι	ND	$< 5\%^d$
6	1b	4-MeOC ₆ H ₄	<i>i</i> -Pr	Acetone	Br	ND	e
7 ^c	1b	4-MeOC ₆ H ₄	<i>i</i> -Pr	Acetone	Ι	65:35 (68:32)	86
8	1b	4-MeOC ₆ H ₄	<i>i</i> -Pr	Acetone	Ι	70:30 (70:30)	89
9	1b	4-MeOC ₆ H ₄	<i>i</i> -Pr	THF	Ι	80:20 (82:18)	92
10	1c	2-ClC ₆ H ₄	<i>i</i> -Pr	Acetone	Br	62:38 (65:35)	91
11 ^c	1c	2-ClC ₆ H ₄	<i>i</i> -Pr	Acetone	Br	52:48	87
12	1c	2- ClC ₆ H ₄	<i>i</i> -Pr	Acetone	Ι		NR
13	1d	Ph	Ph	Acetone	Br/I	ND	e
14	1e	Ph	Ph_2CH	Acetone	Br/I	ND	e
15	1f	4-MeOC ₆ H ₄	Ph	Acetone	Br/I	ND	e
16	1 g	4-MeOC ₆ H ₄	Ph_2CH	Acetone	Br/I	ND	e

^a Determined from the ¹H NMR spectrum of the crude reaction mixture. Ratio in the parentheses refer to the ratio of isolated **3** and **4** after column chromatography.

^b Combined isolated yields of **3** and **4** after chromatography.

^c Reaction at room temperature (25 °C).

 d >90% of **1a** was recovered.

^e Mixture of products. ND: Not determined; NR: No reaction.



compound 3c

compound **4**c

Figure 1. ORTEP diagram of 3c and 4c.

electron-deficient substrate 1c, obtaining moderate diastereoselectivity with good yield (entry 10). Like 1a, when the bromohydrination of 1c was performed at rt, it also showed poor diastereoselectivity (entry 11) as well as not responding to the iodohydrin reaction (entry 12). The configurational assignments for the diastereomeric carboxyhalohydrins 3 and 4 were made by confirming the stereochemistry of 3a and 4a on comparison with the literature data.^{7d,13} This was confirmed by the single crystal X-ray analysis¹⁴ of 3c and 4c (Fig. 1), crystallized from CHCl₃.

Since, the (4*S*)-4-(1-methylethyl)-2-oxazolidinone chiral auxiliary gave moderate to good diastereoselectivities, we also examined other oxazolidinone chiral auxiliaries viz (4*S*)-4-phenyl- and (4*S*)-4-(diphenylmethyl)-2-oxazolidinones.^{10,15} Unfortunately, halohydrin reaction of substrates **1d–1e**, having different oxazolidinone chiral auxiliaries ($\mathbf{R'}$ =Ph, Ph₂CH) using Br₂ and/or I₂, gave mixture of products. Only 12% of an undesired compound was obtained in pure form from the bromohydrin reaction of **1d**. The same compound was obtained in 56% yield, along with minor amount (26%) of another undesired product, when **1d** was treated with AgNO₃ and Br₂ in dry acetone i.e. in the absence of any external nucleophile at 0–5 °C.

Recently, Barluenga et al. found that phenyl group present in the terpene moiety undergoes halocarbocyclization during the iodohydrination of alkenes tethered in terpene derivatives with Py_2IBF_4 .⁶ Spectral analysis of the undesired compounds were found to be bromo-carbocyclized product, but the regio- and stereochemistry of the bromocarbocylized products could not be confirmed. Our several attempts were also failed to get single crystal X-ray difraction quality crystals.¹⁶

To assess whether the counter anion of the Ag(I) salt affects the diastereoselctivity of the halohydrin reactions, product studies were carried out employing the electronically different cinnamoyl substrates **1a–1c**, using AgOAc and Ag₂O instead of AgNO₃ as a promoter, under a variety of reaction conditions (Table 2). AgNO₃ (Eq. 1) and AgOAc (Eq. 2) produce acids on reaction with a halogen in water, whereas Ag₂O does not produce any acid (Eq. 3) under the same reaction conditions. When the halohydrin reactions of **1a-1c** were performed in the presence of AgOAc instead of AgNO₃, similar results were obtained, that is, **3** was produced as the major diastereoisomer (Table 2; entries 1–3). But in the case of Ag₂O-mediated reactions, **1a** and the electron-deficient **1c** showed very poor diastereoselectivities (entries 4 and 6), whereas **1b** still showed **3b** as the

Table 2. AgOAc- and Ag₂O-promoted halohydrin reaction of 1^a

U	02 1	5					
Entry	Substrate	Ag(I) salt	Additive	Х	Ratio ^b (3 : 4)	Yield ^c (%)	
1	1a	AgOAc	None	Br	65:35	94	
2	1b	AgOAc	None	Ι	80:20	91	
3	1c	AgOAc	None	Br	60:40	90	
4	1a	Ag_2O	None	Br	50:50	97	
5	1b	Ag_2O	None	Ι	65:35	88	
6	1c	Ag_2O	None	Br	50:50	94	
7	1a	Ag_2O	HNO ₃	Br	67:33 (66:34)	96 (95)	
8	1b	Ag ₂ O	HNO ₃	Ι	79:21 (77:23)	90 (87)	
9	1c	Ag_2O	HNO ₃	Br	61:39 (62:38)	94 (91)	

^a Halohydrin reactions were performed using 0.7 equiv of Ag₂O and 1.2 equiv of halogen (X₂) in aqueous organic solvent (**1a** and **1c** in aqueous acetone and **1b** in aqueous THF) at 0–5 °C for 30 min.

^b Determined from the ¹H NMR spectrum of the crude reaction mixture.

^c Isolated yields: ratios in parentheses refer to the reactions in the presence of AcOH.

major diastereomer with dr of 65:35 (Table 2; entry 5). When the Ag₂O-promoted halohydrin reactions of **1a–1c** were performed in the presence of either HNO₃ or AcOH as an additive, these showed diastereoselectivities (Table 2; entries 7–9) similar to either AgNO₃- or AgOAc-promoted reactions (Table 1, entries 2, 9 and 10 and Table 2, entries 1–3).

$$AgNO_3 + X_2 + H_2O \rightarrow AgX \downarrow +HOX + HNO_3$$
(1)

$$AgOAc + X_2 + H_2O \rightarrow AgX \downarrow +HOX + AcOH$$
(2)

$$Ag_2O + 2X_2 + 2H_2O \rightarrow 2AgX \downarrow + 2HOX$$
(3)

Unchelated *N*-cinnamoyl-2-oxazolidinone usually exists in the *S*-cis-anti-dipole conformation $\mathbf{1}$,¹⁷ so it was also expected to give carboxyhalohydrin $\mathbf{4}$ as a major diastereoisomer for the above halohydrin reactions, but that was not observed. So it might be concluded here that in



Scheme 2.

 Table 3. AgNO₃-promoted halohydrin reaction of different substrates 1

either AgNO₃ or AgOAc promoted reactions, the H⁺chelated S-cis-syn-dipole conformation 1' might be involved in the halohydrin reaction. The preferred attack of X^+ from the *Re*-face of conformation 1' and subsequent opening of the halonium intermediate 2' by *anti*-nucleophilic attack of H₂O at the β -position yielded **3** as the major diastereoisomer (Scheme 2). The poor diastereoselectivities of the cinnamoyl- and electron-deficient cinnamoyl substrates 1a and 1c in Ag₂O-promoted reactions i.e. under unchelated conditions (Table 2; entries 4 and 6) might be accounted for by the involvement of both the equilibrated Scis- and S-trans-anti-dipole conformations 1 and 1''. The iodohydrination of electron-rich cinnamoyl substrate 1b promoted by Ag₂O, that is, under unchelated conditions still showed carboxyhalohydrin 3b a major diastereoisomer. This could be due to the extensive conjugation of the electron-donating substituent at the p-position with the α,β -unsaturated carbonyls, equilibrium might be shifted more towards the unchelated S-trans-anti-dipole conformation $\mathbf{1}^{"}$ and involve the *Re*-face of *S*-trans-anti-dipole conformation $\mathbf{1}^{"}$, providing **3b** as the major diastereoisomer. This was supported by the Ag₂O-mediated reactions performed in the presence of either HNO₃ or AcOH as an additive (Table 2; entries 7-9).

It was found that either AgNO₃ or AgOAc as a promoter and (4S)-4-(1-methylethyl)-2-oxazolidinone as a chiral auxiliary are a better combination for the Ag(I)-promoted halohydrin reaction. So, to generalize this asymmetric halohydrin reaction, the reaction was further studied for a variety of enoyl substrates containing (4S)-4-(1-methylethyl)-2-oxazolidinone as a chiral auxiliary (Table 3). Substrate 1h possessing strong electron-withdrawing substituents, for example, -NO₂ group on the aromatic ring, smoothly underwent bromohydrin reaction in aqueous acetone under the same reaction conditions with moderate diastereoselectivity (entry 1). Similar to 1c, no iodohydrin reaction was observed for 1h. Substrate 1i with an electron-donating substituent on the aromatic ring efficiently underwent iodohydrin reaction under the same reaction conditions in aqueous acetone with moderate diastereoselectivity (entry 2). Like 1b, the iodohydrin reaction of 1i in aqueous THF provided improved diastereoselectivity (entry 3). Another two electron-rich cinnamoyl substrates 1j and 1k also responded to the iodohydrin reaction in aqueous THF with dr of 82:18 and 78:22, respectively (entries 4 and 5). However, due to instability of the minor isomers 4j and 4k in silica-gel during column chromatography, they could not

	Substrate	R	Solvent	Х	Ratio ^a (3:4)	Yield ^b (%)
1	1 h	$2-NO_2C_6H_4$	Acetone	Br	60:40	86
2	1i	4-BnOC ₆ H ₄	Acetone	I	64:36	91
3	1i	4-BnOC ₆ H ₄	THF	I	80:20	92
4	1j	3, 4-MeOC ₆ H ₃	THF	I	82:18	77 ^c
5	1k	4-BnO-3-MeOC ₆ H ₃	THF	I	78:22	74 ^c
6	11	3, 5-Br-4-BnOC ₆ H ₂	Acetone	Br	65:35	87
7	1m	2-naphthyl	Acetone	I	68:32	88
8	1n	CH ₃	Acetone	Br	62:38 ^d	86 ^e

^a Determined from the ¹H NMR spectrum of the crude reaction mixture.

^b Combined isolated yields of **3** and **4** after chromatography otherwise it is noted.

^c Isolated yield of the isomer **3**.

^d Along with 15% of other regio-isomers

^e Combined isolated yield of **3n**, **4n** and the other regio-isomers.

be obtained in pure form. While the bromohydrin reaction of **1i–1k** were performed under the same reaction conditions; these gave a mixture of products. We have also studied the halohydrin reaction of electronically different cinnamoyl substrates, where 11 behaved like an electron-deficient cinnamoyl substrate, that is, responded to the bromohydrin reaction in aqueous acetone (entry 6) but no iodohydrin reaction. On the other hand, 1m acted as an electron-rich cinnamoyl substrate and smoothly underwent iodohydrin reaction in aqueous acetone (entry 7), whereas bromohydrin reaction gave mixture of products. We have also studied the halohydrin reaction of alkenoyl substrate 1n. This responded to the bromohydrin reaction with moderate diastereoselectivity (entry 8), along with 15% of other regio-isomers, minor isomer 4n was always obtained as a non-separable mixture with regio-isomers.

3. Conclusion

In conclusion, we have described Ag(I)-promoted asymmetric halohydrin reaction of chiral N-enoyl-2-oxazolidinones 1 with high regio- and *anti*-selectivity and moderate to good diastereoselectivity in good yields. Alkenoyl, cinnamoyl and electron-deficient cinnamoyl substrates smoothly undergo bromohydrin reactions but no iodohydrin reactions, whereas electron-rich cinnamoyl substrates prefer to undergo iodohydrin reactions. AgNO3 and AgOAc are found to be better promoters than Ag₂O for promoting diastreoselectivity. It was found that the acids produced on reactions of AgNO₃ and AgOAc with halogen in aqueous media were responsible for the involvement of the H⁺-chelated S-cis-syn-dipole conformation and provided better diastereoselectivity for the halohydrin reactions of N-enol-2-oxazolidinoes. It was also found that the oxazolidinone chiral auxiliary should contain alkyl substituents, more specifically non-nucleophilic substituents; otherwise that would act as a competitive nucleophile. This methodology, that is, the direct use of halogen and water promoted by Ag(I), offers an alternative method for the asymmetric synthesis of carboxyhalohydrins, that is, anti-a-halo-βhydroxycarboxylic acid derivatives. We are currently applying the concept of halohydrin reaction to other halonucleophilic (X⁺ Nu⁻) addition reactions for the asymmetric 1,2-hetero-bifunctionalization of alkenes.

4. Experimental

The ¹H NMR spectra were measured on a Bruker-200 (200 MHz) and Bruker-500 (500 MHz) using CDCl₃ as solvent. The ¹³C NMR spectra were measured with Bruker-200 (50 MHz) and Bruker-500 (125 MHz) using CDCl₃ as solvent. ¹H NMR chemical shifts are expressed in parts per million (δ) downfield to CHCl₃ (δ =7.26); ¹³C NMR chemical shifts are expressed in parts per million (δ) relative to the central CDCl₃ resonance (δ =77.0). Coupling constants in ¹H NMR are in Hz. IR spectra were recorded using Thermo Nicolet FT-IR spectroscopy. Elemental analyses were carried out using Perkin–Elmer 2400-II and mass spectra were analyzed by Waters LCT mass spectrometer.

Commercial grade reagents were used without further purification. Solvents are used after distillation following usual protocols. For the halohydrin reaction distilled water is used. Flash chromatography was carried out using Acme silica gel (230–400 mesh). Substrates **1** were synthesized following the literature procedures.^{10,18}

4.1. General experimental procedure for the halohydrin reaction

To a solution of the substrate 1 (1 mmol) in aqueous organic solvent (20 ml; acetone or THF; organic solvent/H₂O 4:1) Ag(I) (for AgNO₃ and AgOAc 1.2 mmol and Ag₂O (0.7 mmol) and halogen (Br₂ or I₂, 1.2 mmol) were added, respectively, at 0–5 °C and allowed to stir for 20–30 min. The reaction mixture was extracted with Et₂O at least three times, washed with water, dried over Na₂SO₄. The organic solution was filtered through a small cellite pad (otherwise locking problem or poor base line was found in the ¹H NMR of the crude mixture) and the filtrate was concentrated under vacuum. Flash column chromatography of the crude mixture using petroleum ether-EtOAc as eluent gave desired carboxyhalohydrins in pure form.

4.1.1. *anti*-(**4***S*, **2**′*S*, **3**′*S*)-**3**-[**3**′-**Hydroxy**-**2**′-iodo-**3**′-(**4**-**methoxyphenyl**)-**propionyl**]-**4**-(**1**-**methylethyl**)-**2**-**oxazo**lidinone (**3b**). Gummy liquid, $[\alpha]_{21}^{21}$ + 88.4° (*c* 1.0, CHCl₃); FTIR (KBr) 3459 (br, OH), 2963, 2837, 1778, 1694, 1612, 1586, 1515, 1484, 1463, 1387, 1303, 1250, 1205, 1178, 1142, 1103, 1022, 971, 835, 789, 768, 728, 694, 565 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.33 (d, *J*=8.6 Hz, 2H), 6.89 (d, *J*=8.6 Hz, 2H), 6.13 (d, *J*=7.9 Hz, 1H), 5.15 (d, *J*=7.9 Hz, 1H), 4.47 (m, 1H), 4.30–4.20 (m, 2H), 3.80 (s, 3H), 3.40 (br s, 1H), 2.5–2.33 (m, 1H), 0.95 (t, *J*=6.3 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 170.9, 159.7, 152.9, 131.7, 128.3 (2C), 113.9 (2C), 75.4, 63.4, 58.2, 55.2, 27.9, 25.0, 17.7, 15.0. Anal. Calcd for C₁₆H₂₀INO₅: C, 44.36; H, 4.65; N, 3.23. Found: C, 44.18; H, 4.45; N, 2.92%.

4.1.2. *anti*-(**4***S*, **2**′*R*, **3**′*R*)-**3**-[**3**′-Hydroxy-**2**′-iodo-**3**′-(**4**-methoxyphenyl)-propionyl]-**4**-(**1**-methylethyl)-**2**-oxazo-lidinone (**4b**). Gummy liquid; $[\alpha]_{D}^{22} + 8.6^{\circ}$ (*c* 1.0, CHCl₃); FTIR (KBr) 3473 (br OH), 2962, 2929, 1777, 1697, 1611, 1514, 1485, 1463, 1386, 1303, 1250, 1202, 1177, 1120, 1030, 972, 830, 789, 769, 694, 562 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.33 (d, *J*=8.7 Hz, 2H), 6.87 (d, *J*= 8.7 Hz, 2H), 6.18 (d, *J*=7.0 Hz, 1H), 5.10 (d, *J*=7.0 Hz, 1H), 4.49–4.11 (m, 3H), 3.79 (s, 3H), 2.37–2.12 (m, 1H), 0.85 (d, *J*=7.0 Hz, 3H), 0.65 (d, *J*=7.0 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 171.2, 159.7, 153.0, 131.6, 128.0 (2C), 113.9 (2C), 75.8, 63.4, 59.0, 55.3, 28.5, 23.8, 17.8, 14.3. Anal. Calcd for C₁₆H₂₀INO₅: C, 44.36; H, 4.65; N, 3.23. Found: C, 44.54; H, 4.86; N, 3.02%.

4.1.3. *anti*-(4*S*, 2'*S*, 3'*S*)-3-[2'-Bromo-3'-hydroxy-3'-(2chlorophenyl)-propionyl]-4-(1-methylethyl)-2-oxazolidinone (3c). Mp 108–109 °C; $[\alpha]_D^{22}$ +69.9° (*c* 1.0, CHCl₃); FTIR (KBr) 3450 (br OH), 2964, 2920, 2849, 1782, 1702, 1464, 1439, 1386, 1302, 1203, 1120, 1049, 1024, 971, 763, 717, 686, 636, 599, 465 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.55–7.51 (m, 1H), 7.42–7.24 (m, 3H), 6.12 (d, *J*=7.3 Hz, 1H), 5.66 (br d, 1H), 4.44 (m, 1H), 4.23 (m, 2H), 3.72 (br s, 1H), 2.5–2.3 (m, 1H), 0.93 (d, *J*=7.0 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 169.0, 152.7, 136.5, 133.4, 129.8, 129.7, 128.4, 127.2, 71.7, 63.5, 58.3, 43.1, 28.0, 17.8, 14.8. Anal. Calcd for C₁₅H₁₇BrClNO₄: C, 46.12; H, 4.39; N, 3.59. Found: C, 46.08; H, 4.18; N, 3.59%.

4.1.4. *anti*-(**4***S*, **2**′*R*, **3**′*R*)-**3**-[**2**′-Bromo-**3**′-hydroxy-**3**′-(**2**-chlorophenyl)-propionyl]-**4**-(**1**-methylethyl)-**2**-oxazolidinone (**4c**). Mp 123–124 °C; $[\alpha]_{D}^{21}$ – 6.4° (*c* 1.0, CHCl₃); FTIR (KBr) 3455 (br OH), 2964, 2926, 1779, 1703, 1676, 1593, 1483, 1465, 1438, 1385, 1301, 1201, 1120, 1049, 1023, 973, 755, 718, 684, 669, 632, 464 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.60–7.45 (m, 1H), 7.40–7.20 (m, 3H), 6.22 (d, *J*=6.5 Hz, 1H), 5.58 (d, *J*=6.5 Hz, 1H), 4.42 (m, 1H), 4.33–4.14 (m, 2H), 2.30–2.15 (m, 1H), 0.86 (d, *J*=7.0 Hz, 3H), 0.60 (d, *J*=7.0 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 169.1, 152.8, 136.5, 133.2, 129.7, 129.6, 128.2, 127.1, 72.3, 63.4, 58.9, 42.0, 28.3, 17.7, 14.3. Anal. Calcd for C₁₅H₁₇BrClNO₄: C, 46.12; H, 4.39; N, 3.59. Found: C, 46.34; H, 4.24; N, 3.54%.

4.1.5. *anti*-(**4***S*, **2**′*S*, **3**′*S*)-**3**-[**2**′-Bromo-**3**′-hydroxy-**3**′-(**2**-nitrophenyl)-propionyl]-**4**-(**1**-methylethyl)-**2**-oxazolidinone (**3h**). Mp 155–156 °C; $[\alpha]_{D}^{23}$ +113.6° (*c* 1.0, CHCl₃); FTIR (KBr) 3381 (br OH), 2965, 1748, 1707, 1529, 1488, 1403, 1393, 1364, 1300, 1281, 1227, 1217, 1143, 1119, 1043, 1018, 972, 853, 780, 749, 719, 674, 608, 504 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.95 (dd, *J*=8.0, 0.9 Hz, 1H), 7.85–7.60 (m, 2H), 7.57–7.45 (m, 1H), 6.08 (d, *J*= 8.0 Hz, 1H), 5.93 (d, *J*=8.0 Hz, 1H), 4.49 (m, 1H), 4.35–4.18 (m, 2H), 3.75 (br s, 1H), 2.50–2.33 (m, 1H), 0.94 (d, *J*=7.0 Hz, 3H), 0.92 (d, *J*=7.0 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 168.4, 152.8, 149.1, 133.7, 133.3, 129.4, 129.3, 124.6, 69.6, 63.6, 58.3, 43.8, 28.0, 17.7, 14.7. Anal. Calcd for C₁₅H₁₇BrN₂O₆: C, 44.90; H, 4.27; N, 6.98. Found: C, 44.60; H, 4.03; N, 6.73%.

4.1.6. *anti*-(**4***S*, **2**′*R*, **3**′*R*)-**3**-[**2**′-Bromo-**3**′-hydroxy-**3**′-(**2**-nitrophenyl)-propionyl]-**4**-(**1**-methylethyl)-**2**-oxazolidinone (**4**h). Gummy liquid; $[\alpha]_{22}^{22} - 39.1^{\circ}$ (*c* 1.0, CHCl₃); FTIR (KBr) 3453 (br OH), 2964, 2927, 2876, 1779, 1704, 1608, 1580, 1529, 1485, 1464, 1386, 1351, 1300, 1203, 1142, 1120, 1052, 1020, 972, 853, 786, 750, 713, 672 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.97 (dd, *J*=8.0, 0.9 Hz, 1H), 7.87–7.60 (m, 2H), 7.57–7.42 (m, 1H), 6.16 (d, *J*= 7.4 Hz, 1H), 5.90 (d, *J*=7.4 Hz, 1H), 4.43 (m, 2H), 4.40–4.15 (m, 2H), 2.48–2.15 (m, 1H), 0.89 (d, *J*=7.0 Hz, 3H), 0.71 (d, *J*=7.0 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 168.6, 152.9, 148.9, 134.1, 133.4, 129.3, 129.0, 124.8, 70.6, 63.6, 59.1, 42.6, 24.4, 17.7, 14.5. Anal. Calcd for C₁₅H₁₇BrN₂O₆: C, 44.90; H, 4.27; N, 6.98. Found: C, 44.67; H, 4.13; N, 6.73%.

4.1.7. *anti*-(**4***S*, **2***'S*, **3***'S*)-**3**-[**3***'***Hydroxy**-**2***'*-iodo-**3***'*-(**4**-ben-zyloxyphenyl)-propionyl]-**4**-(**1**-methylethyl)-2-oxazolidinone (**3i**). Mp 163–164 °C; $[\alpha]_D^{22}$ +63.0° (*c* 1.0, CHCl₃); FTIR (KBr) 3465 (br OH), 3033, 2959, 2921, 2874, 1768, 1678, 1608, 1515, 1487, 1455, 1429, 1388, 1366, 1329, 1307, 1247, 1221, 1206, 1178, 1119, 1101, 1078, 1049, 1021, 1003, 970, 922, 857, 841, 821, 800, 760, 749, 729, 702, 694, 626, 562, 509, 490 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.50–7.25 (m, 7H), 6.97 (d, *J*=8.7 Hz, 2H), 6.13 (d, *J*=7.9 Hz, 1H), 5.16 (d, *J*=7.9 Hz, 1H), 5.06 (s, 2H), 4.52–4.38 (m, 1H), 4.33–4.18 (m, 2H), 3.44 (br s, 1H), 2.51–

2.30 (m, 1H), 0.96 (quasi t, J = 5.90, 6.8 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 171.0, 159.0, 152.9, 136.8, 131.9, 128.5 (2C), 128.3 (2C), 128.0, 127.4 (2C), 114.9 (2C), 75.5, 70.1, 63.0, 58.2, 28.0, 24.9, 17.8, 15.1. Anal. Calcd for C₂₂H₂₄INO₅: C, 51.88; H, 4.75; N, 2.75. Found: C, 51.99; H, 4.79; N, 2.67%.

4.1.8. *anti*-(4*S*, 2'*R*, 3'*R*)-3-[3'-Hydroxy-2'-iodo-3'-(4benzyloxyphenyl)-propionyl]-4-(1-methylethyl)-2-oxazolidinone (4i). Gummy liquid, $[\alpha]_D^{23} + 8.6^{\circ} (c \ 1.0, CHCl_3)$; FTIR (KBr) 3459 (br OH), 2962, 2925, 1777, 1695, 1609, 1512, 1485, 1463, 1454, 1384, 1302, 1202, 1175, 1120, 1020, 829, 738, 697, 624, 558 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.48–7.25 (m, 7H), 6.96 (d, *J*=8.7 Hz, 2H), 6.19 (d, *J*=7.0 Hz, 1H), 5.13–5.05 (m, 3H), 4.51–4.08 (m, 3H), 3.63 (br d, *J*=7.0 Hz, 1H), 2.32–2.15 (m, 1H), 0.84 (d, *J*= 7.0 Hz, 3H), 0.64 (d, *J*=7.0 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 171.1, 158.9, 153.0, 136.8, 131.9, 128.5 (2C), 128.0 (2C), 127.9, 127.3 (2C), 114.9 (2C), 75.8, 70.0, 63.4, 58.9, 28.4, 23.7, 17.7, 14.3. Anal. Calcd for C₂₂H₂₄INO₅: C, 51.88; H, 4.75; N, 2.75. Found: C, 51.93; H, 4.57; N, 2.75%.

4.1.9. *anti*-(4*S*, 2'*S*, 3'*S*)-3-[3'-Hydroxy-2'-iodo-3'-(3,4dimethoxyphenyl)-propionyl]-4-(1-methylethyl)-2-oxazolidinone (3j). Mp 164–165 °C; $[\alpha]_D^{23}$ +54.6° (*c* 1.0, CHCl₃); FTIR (KBr) 3473 (br OH), 3024, 2964, 1761, 1702, 1607, 1591, 1517, 1484, 1465, 1448, 1438, 1421, 1388, 1365, 1332, 1298, 1262, 1236, 1218, 1201, 1160, 1137, 1119, 1105, 1071, 1052, 1024, 1002, 969, 889, 835, 761, 700, 655, 618, 576 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.10–6.70 (m, 3H), 6.17 (d, *J*=7.6 Hz, 1H), 5.13 (d, *J*= 7.6 Hz, 1H), 4.45 (m, 1H), 4.25 (m, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 2.51–2.30 (m, 1H), 0.95 (t, *J*=6.5 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 171.0, 152.8, 149.0, 148.9, 131.9, 119.4, 110.9, 109.8, 75.6, 63.3, 58.1, 55.9, 55.8, 27.8, 24.6, 17.8, 15.0. Anal. Calcd for C₁₇H₂₂INO₆: C, 44.07; H, 4.79; N, 3.02. Found: C, 44.11; H, 4.77; N, 2.85%.

4.1.10. anti-(4S, 2'S, 3'S)-3-[3'-Hydroxy-2'-iodo-3'-(4benzyloxy-3-methoxyphenyl)-propionyl]-4-(1-methylethyl)-2-oxazolidinone (3k). Gummy liquid: $\left[\alpha\right]_{D}^{23} + 64.3^{\circ}$ (c 1.0, CHCl₃); FTIR (KBr) 3455 (br OH), 2963, 2929, 2875, 1778, 1694, 1594, 1514, 1485, 1463, 1454, 1422, 1386, 1303, 1262, 1203, 1141, 1102, 1020, 971, 912, 857, 804, 767, 734, 697, 648, 617, 563, 456 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.50–725 (m, 7H), 6.94 (s, 1H), 6.87 (m, 2H), 6.15 (d, J = 7.6 Hz, 1H), 5.14 (m, 3H), 4.48–4.35 (m, 1H), 4.29-4.16 (m, 2H), 3.90 (s, 3H), 3.57 (br s, 1H), 2.50–2.31 (m, 1H), 0.94 (t, J=6.6 Hz, 6H), ¹³C NMR (50 MHz, CDCl₃) δ 170.9, 152.7, 149.5, 148.1, 136.8, 132.4, 128.4 (2C), 127.4, 127.1 (2C), 119.2, 113.5, 110.3, 75.6, 70.8, 63.2, 58.0, 55.9, 27.7, 24.5, 17.7, 14.9. Anal. Calcd for C₂₃H₂₆INO₆: C, 51.22; H, 4.86; N, 2.60. Found: C, 51.06; H, 4.91; N, 2.68%.

4.1.11. *anti*-(4*S*, 2'*S*, 3'*S*)-3-[2'-Bromo-3'-hydroxy-3'-(4benzyloxy-3, 5-dibromophenyl)-propionyl]-4-(1-methylethyl)-2-oxazolidinone (3l). Mp 170–171 °C; $[\alpha]_D^{22}$ +45.6° (*c* 1.0, CHCl₃); FTIR (KBr) 3448 (br OH), 2960, 2922, 2853, 1781, 1700, 1645, 1456, 1380, 1256, 1200, 1116, 1047, 742, 701, 620, 532 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.65–7.55 (m, 4H), 7.51–7.32 (m, 3H), 5.74 (d, *J*=8.3 Hz, 1H), 5.12 (d, *J*=8.3 Hz, 1H), 5.03 (s, 2H), 4.50 (m, 1H), 4.42–4.18 (m, 2H), 2.67 (br s, 1H), 2.52–2.25 (m, 1H), 0.99 (d, J=7.1 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 168.7, 152.9, 152.8, 137.8, 136.0, 131.6 (2C), 128.4 (5C), 118.5 (2C), 74.6, 73.3, 63.6, 58.3, 44.6, 28.0, 17.7, 14.7. Anal. Calcd for C₂₂H₂₂Br₃NO₅: C, 42.61; H, 3.58; N, 2.26. Found: C, 42.86; H, 3.42; N, 2.19%.

4.1.12. *anti*-(**4***S*, **2**′*R*, **3**′*R*)-**3**-[**2**′-Bromo-**3**′-hydroxy-**3**′-(**4**-benzyloxy-**3**, **5**-dibromophenyl)-propionyl]-**4**-(**1**-methyl-ethyl)-**2**-oxazolidinone (**4**l). Gummy liquid, $[\alpha]_{22}^{22}$ +6.88° (*c* 1.0, CHCl₃); FTIR (KBr) 3473 (br OH), 3064, 3032, 2963, 2926, 2874, 1781, 1705, 1548, 1497, 1485, 1455, 1386, 1303, 1256, 1202, 1141, 1105, 1053, 1019, 970, 914, 875, 740, 697, 632, 537 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.65–7.45 (m, 4H), 7.44–7.33 (m, 3H), 5.87 (d, *J*=7.4 Hz, 1H), 5.09 (d, *J*=7.4 Hz, 1H), 5.03 (s, 2H), 4.45 (m, 1H), 4.40–4.19 (m, 2H), 2.42–2.18 (m, 1H), 0.84 (d, *J*=6.9 Hz, 3H), 0.75 (d, *J*=6.9 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 168.8, 153.0, 152.8, 137.9, 135.9, 131.4 (2C), 128.4 (5C), 118.6 (2C), 74.6, 73.8, 63.6, 59.0, 43.9, 28.4, 17.7, 14.4. Anal. Calcd for C₂₂H₂₂Br₃NO₅: C, 42.61; H, 3.58; N, 2.26. Found: C, 42.45; H, 3.52; N, 2.08%.

4.1.13. *anti*-(**4***S*, **2**′*S*, **3**′*S*)-**3**-[**3**′-**Hydroxy**-**2**′-iodo-**3**′-(**2**-**naphthyl**)-**propionyl**]-**4**-(**1**-methylethyl)-**2**-oxazolidinone (**3m**). Mp 90–91 °C; $[\alpha]_{D}^{22}$ + 118.3° (*c* 0.8, CHCl₃); FTIR (KBr) 3444 (br OH), 2963, 2925, 1779, 1693, 1601, 1386, 1304, 1202, 1142, 1122, 1049, 1019, 819, 749, 694, 479 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.90–7.75 (m, 4H), 7.55–7.45 (m, 3H), 6.30 (d, *J*=7.6 Hz, 1H), 5.33 (d, *J*=7.6 Hz, 1H), 4.41 (m, 1H), 4.19 (m, 2H), 2.49–2.28 (m, 1H), 0.94 (t, *J*=7.5 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 171.0, 152.8, 136.8, 133.3, 133.0, 128.5, 128.2, 127.6, 126.6, 126.3 (2C), 124.2, 76.1, 63.4, 58.1, 27.9, 24.2, 17.7, 15.0. Anal. Calcd for C₁₉H₂₀INO₄: C, 50.35; H, 4.45; N, 3.09. Found: C, 50.40; H, 4.42; N, 3.02%.

4.1.14. *anti*-(4*S*, 2'*R*, 3'*R*)-3-[3'-Hydroxy-2'-iodo-3'-(2-naphthyl)-propionyl]-4-(1-methylethyl)-2-oxazolidinone (4m). Gummy liquid, $[\alpha]_{D}^{22}$ + 14.4° (*c* 0.5, CHCl₃); FTIR (KBr) 3458 (br OH), 2963, 1777, 1694, 1601, 1463, 1385, 1303, 1272, 1199, 1120, 1056, 1019, 819, 750, 693, 479 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.90–7.78 (m, 4H), 7.55–7.45 (m, 3H), 6.35 (d, *J*=6.7 Hz, 1H), 5.29 (d, *J*=6.7 Hz, 1H), 4.42–4.08 (m, 3H), 3.90 (br s, 1H), 2.19–1.95 (m, 1H), 0.76 (d, *J*=7.0 Hz, 3H), 0.37 (d, *J*=7.0 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 171.1, 152.9, 136.6, 133.2, 133.0, 128.4, 128.0, 127.5, 126.2 (2C), 126.1, 124.0, 76.2, 63.3, 58.8, 28.3, 22.8, 17.6, 13.9. Anal. Calcd for C₁₉H₂₀INO₄: C, 50.35; H, 4.45; N, 3.09. Found: C, 50.26; H, 4.26; N, 3.03%.

4.1.15. *anti*-(**4***S*, **2**'*S*, **3**'*S*)-**3**-(**2**'-**Bromo**-**3**'-**hydroxy-butio**-**nyl**)-**4**-(**1-methylethyl**)-**2**-**oxazolidinone** (**3n**). Gummy liquid, $[\alpha]_{D^2}^{D^2}$ + 60.7° (*c* 1.0, CHCl₃); FTIR (KBr) 3442 (br OH), 1783, 1708, 1389, 1333, 1215, 1117, 1028, 772, 714 cm⁻¹. ¹H NMR (200 MHz, CDCl₃) δ 5.43 (d, *J*= 8.3 Hz, 1H); 4.40 (m, 1H); 4.31–4.18 (m, 5H); 3.58 (br s, 1H), 2.39–2.27 (m, 1H); 1.40 (d, *J*=6.3 Hz, 3H); 0.87 (d, *J*=7.0 Hz, 3H); 0.83 (d, *J*=7.0 Hz, 3H). ¹³C NMR (50 MHz, CDCl₃) δ 169.5, 153.8, 69.6, 64.2, 59.7, 47.0, 29.0, 20.5, 18.3, 15.1. MS (*m*/*z*) for C₁₀H₁₆BrNO₄: calculated (M+H)⁺ 294.024, found 294.015 (M+H)⁺,

296.013 $(M+H+2)^+$. Anal. Calcd for $C_{10}H_{16}BrNO_4$: C, 40.83; H, 5.48; N, 4.76. Found: C, 40.48; H, 5.31; N, 4.75%.

4.1.16. *anti*-(**4***S*, **2**′*R*, **3**′*R*)-**3**-(**2**′-**Bromo**-**3**′-**hydroxy-butionyl**)-**4**-(**1-methylethyl**)-**2-oxazolidinone** (**4n**). Oily liquid, $[\alpha]_{D}^{2D}$ + 18.4° (*c* 1.0, CHCl₃); FTIR (KBr) 3445 (br OH), 1773, 1702, 1377, 1318, 1200, 1104, 1012, 767, 708, 655 cm⁻¹. ¹H NMR (200 MHz, CDCl₃) δ 5.35 (d, *J*= 8.6 Hz, 1H); 4.45 (m, 1H); 4.30–4.17 (m, 5H); 2.70 (br S, 1H), 2.37–2.27 (m, 1H); 1.39 (d, *J*=6.3 Hz, 3H); 0.87 (dd, *J*=2.4, 6.9 Hz, 6H). ¹³C NMR (50 MHz, CDCl₃) δ 169.6, 153.4, 68.8, 64.0, 58.7, 46.8, 28.5, 20.4, 18.2, 15.2. Anal. Calcd for C₁₀H₁₆BrNO₄: C, 40.83; H, 5.48; N, 4.76. Found: C, 40.46; H, 5.17; N, 4.86%.

4.1.17. *anti*-(4*S*)-3-(2',3'-Dibromo-3'-phenyl-propionyl)-**4-(1-methylethyl)-2-oxazolidinone (5a).** Non-seperable mixture of diastereomers (60:40); light yellow solid, mp 76–80 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.60–7.26 (m, 5H), 6.58 (d, *J*=11.6 Hz, 1H), 5.51 (d, *J*=11.6 Hz, 1H), 4.65–4.50 (m, 1H), 4.47–4.20 (m, 2H), 2.60–2.40 (m, 1H), 0.98 (d, *J*=6.8 Hz, 1.8H), 0.97 (d, *J*=6.9 Hz, 2.4H), 0.95 (d, *J*=6.8 Hz, 1.8H). ¹³C NMR (125 MHz, CDCl₃): major δ 167.6, 153.6, 138.0, 129.9, 129.4 (2C), 128.8 (2C), 64.1, 58.9, 50.6, 44.3, 28.5, 18.2, 15.3. minor δ 167.8, 153.5, 137.9, 129.8, 129.3 (2C), 128.7 (2C), 63.9, 59.5, 51.2, 43.9, 28.7, 18.3, 15.2.

4.2. Bromocarbocyclized product

4.2.1. Major compound. White amorphous solid, mp 156–158 °C. FTIR (KBr) 1760, 1706, 1450, 1382, 1304, 1187, 1109, 1008, 750, 693, 589, 532, 485 cm⁻¹. ¹H NMR (200 MHz, CDCl₃) δ 7.40–7.20 (m, 9H); 6.01 (d, *J*=7.4 Hz, 1H); 4.45 (dd, *J*=8.8, 3.4 Hz, 1H); 5.08 (d, *J*=7.4 Hz, 1H); 4.74 (t, *J*=8.7 Hz, 1H); 4.25 (dd, *J*=8.8, 3.4 Hz, 1H). ¹³C NMR (50 MHz, CDCl₃) δ 168.8, 152.5, 138.6, 137.7, 129.0 (3C), 128.3 (3C), 126.6 (2C), 125.2 (2C), 75.0, 69.9, 57.7, 44.1. MS (ESI; *m*/*z*) for C₁₈H₁₄BrNO₃ calculated (M+H)⁺ 372.024, found 371.996 (M+H)⁺, 373.995 (M+H+2)⁺. Anal. Calcd for (C₁₈H₁₄BrNO₃+1H₂O): C, 55.40; H, 4.13; N, 3.59. Found: C, 55.53; H, 4.04; N, 3.75%.

4.2.2. Minor compound. White amorphous solid, mp 151–153 °C, FTIR (KBr) 1777, 1696, 1460, 1399, 1338, 1224, 1130, 1076, 1040,766, 685, 604, 523 cm⁻¹. ¹H NMR (200 MHz, CDCl₃) δ 7.60–7.20 (m, 9H); 5.91 (d, *J*=8.2 Hz, 1H); 5.44 (dd, *J*=8.6, 4 Hz, 1H); 5.12 (d, *J*=8.2 Hz, 1H); 4.68 (t, *J*=9 Hz, 1H); 4.26 (dd, *J*=8.6, 4 Hz, 1H) ¹³C NMR (50 MHz, CDCl₃) δ 168.9, 153.1, 139.4, 138.1, 129.7 (2C), 129.4, 129.2, 129.0 (2C), 127.6 (2C), 126.1 (2C), 75.2, 70.5, 58.1, 45.5. Anal. Calcd for (C₁₈H₁₄BrNO₃ + 1H₂O): C, 55.40; H, 4.13; N, 3.59. Found: C, 55.38; H, 3.98; N, 3.75%.

Acknowledgements

We thank CSIR, New Delhi and DST, New Delhi for providing financial support and Dr. K. Biradha for the single crystal X-ray analysis. A. K. thanks CSIR, New Delhi and M. B. thanks IIT, Kharagpur for their fellowships.

References and notes

- (a) Ohno, M.; Otsuka, M. In *Recent Progress in Chemical Synthesis of Antibiotics*; Lukas, G., Ohno, M., Eds.; Springer: New York, 1990. (b) Dong, L.; Miller, M. J. *J. Org. Chem.* **2002**, 67, 4759. (c) Evans, D. A.; Ellman, J. A.; DeVries, K. M. *J. Am. Chem. Soc.* **1989**, *111*, 8912. (d) Evans, D. A.; Weber, A. E. *J. Am. Chem. Soc.* **1987**, *109*, 7151. (e) Tseng, T. C.; Wu, M. J. *Tetrahedron: Asymmetry* **1995**, 6, 1633. (f) Nicolaou, K. C.; Kataoka, T. C.; Caulfield, T.; Kumazawa, T. *J. Am. Chem. Soc.* **1988**, *110*, 7910. (g) Sheehan, J. C.; Mania, D.; Nakamura, S.; Stock, J. A.; Maeda, K. *J. Am. Chem. Soc.* **1968**, *90*, 462. (h) Boger, D. L.; Memezes, R. F. *J. Org. Chem.* **1992**, *57*, 4331.
- (a) Ishihara, T.; Mima, K.; Konno, T.; Yamanaka, H. *Tetrahedron Lett.* **2002**, *43*, 3493. (b) Guindon, Y.; Rancourt, J. J. Org. Chem. **1998**, *63*, 6554. (c) Nagano, H.; Kuno, Y.; Omori, Y.; Iguchi, M. J. Chem. Soc., Perkin Trans. 1 **1996**, 389. (d) Hart, D. J.; Krishnamurthy, R. J. Org. Chem. **1992**, *57*, 4457.
- (a) House, H. O. *Modern Synthetic Reaction* 2nd ed.; WA Benjamin Inc.: Menlo Park, CA, 1972; pp 322–326. (b) March, J. Advanced Organic Chemistry 4th ed.; Wiley: New York, 1992; pp 813–815. (c) Carey, F.; Sundberg, R. Advanced Organic Chemistry, Part B 4th ed.; Plenum: New York, 2001; pp 202–205.
- El-Qisairi, A.; Hamed, O.; Henry, P. M. J. Org. Chem. 1998, 63, 2790.
- Dewkar, G. K.; Srinivasarao, V. N.; Sudalai, A. Org. Lett. 2003, 5, 4501.
- Barluenga, J.; Alvarez-Perez, M.; Rodriguez, F.; Fananas, F. J.; Cuesta, J. A.; Garcia-Granda, S. *J. Org. Chem.* 2003, *68*, 6583.
- (a) Evans, D. A.; Weber, A. E. J. Am. Chem. Soc. 1986, 108, 6757. (b) Abdel-Magid, A.; Pridgen, L. N.; Eggleston, D. S.; Lantos, I. J. Am. Chem. Soc. 1986, 108, 4595. (c) Evans, D. A.; Sjogren, E. B.; Weber, A. E.; Conn, R. E. Tetrahedron Lett. 1987, 28, 39. (d) Pridgen, L. N.; Abdel-Magid, A.; Lantos, I.; Shilcrat, S.; Eggleston, D. S. J. Org. Chem. 1993, 58, 5107.

- Genet, J. P.; de Andrade, M. C. C.; Vidal, V. R. *Tetrahedron Lett.* **1995**, *36*, 2063.
- 9. (a) Review: Bonini, C.; Righi, G. Synthesis 1993, 225.
 (b) Righi, G.; Rumboldt, G.; Bonini, C. Tetrahedron 1995, 51, 13401. (c) Righi, G.; Chionne, A.; D'Achille, R.; Bonini, C. Tetrahedron: Asymmetry 1998, 8, 903. (d) Amantini, D.; Fringuelli, F.; Pizzo, F.; Vaccaro, L. J. Org. Chem. 2001, 66, 4463.
- (a) McKennon, M. J.; Meyers, A. I. J. Org. Chem. 1993, 58, 3568. (b) Evans, D. A.; Mathre, D. J.; Scott, W. L. J. Org. Chem. 1985, 50, 1830. (c) Evans, D. A.; Dow, R. L.; Shih, T. L.; Takacs, J. M.; Zahler, R. J. Am. Chem. Soc. 1990, 112, 5290.
- (a) Ayres, T. C.; Loike, J. D. Lignans. Chemical, Biological and Clinical Properties; Cambridge University Press: Cambridge, 1990. (b) Ward, R. S. Chem. Soc. Rev. 1982, 11, 75.
- (a) Masuda, H.; Takase, K.; Nishio, M.; Hasegawa, A.; Nishiyama, Y.; Ishii, Y. *J. Org. Chem.* **1994**, *59*, 5550.
 (b) Guindon, Y.; Yoakim, C.; Gorys, V.; Ogilvie, W. W.; Delorme, D.; Renaud, J.; Robinson, G.; Lavallee, J.-F.; Slassi, A.; Jung, G.; Rancourt, J.; Durkin, K.; Liotta, D. *J. Org. Chem.* **1994**, *59*, 1166. (c) Vishwakarma, L. C.; Walia, J. S. *J. Ind. Chem. Soc.* **1976**, *53*, 156.
- 13. Pridgen, L. N.; Brosse, C. D. J. Org. Chem. 1997, 62, 216.
- Crystallographic data (excluding structure factors) for the structure, have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 252166 (compound 3c) and 252167 (compound 4c).
- Sibi, M. P.; Deshpande, P. K.; La Loggia, A. J.; Christensen, J. W. Tetrahedron Lett. 1995, 36, 8961.
- Crystalized from CH₂Cl₂, CHCl₃, CCl₄, C₆H₆, C₆H₅CH₃, Et₂O, CH₃COOEt, CH₃COCH₃, CH₃CN, MeOH, EtOH, *i*-PrOH, *t*-BuOH and their sixty different combinations.
- (a) Evans, D. A.; Chapman, K. T.; Bisaha, J. J. Am. Chem. Soc. 1988, 110, 1238. (b) Montaudo, G.; Librando, V.; Caccamese, S.; Maravigna, P. J. Am. Chem. Soc. 1973, 95, 6365.
- Rajagopalan, S.; Raman, P. V. A. Org. Synth. Coll. Vol. III, p 425, Wiley, 1955.